Loading...
XSHE
000952
Market cap300mUSD
Jun 11, Last price  
6.28CNY
1D
-0.16%
1Q
9.03%
Jan 2017
-60.58%
Name

Hubei Guangji Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
P/S
2.93
EPS
Div Yield, %
Shrs. gr., 5y
3.32%
Rev. gr., 5y
-2.65%
Revenues
738m
-7.50%
276,625,120345,834,010388,696,038794,903,350571,782,750448,197,426483,316,187453,316,737394,156,326487,080,365485,858,038560,355,471714,723,953801,556,325843,830,942731,340,517688,169,323837,106,649797,642,746737,819,479
Net income
-140m
L
8,213,3818,563,82915,664,893183,801,72589,097,44543,003,75313,979,6024,845,51002,421,979020,921,468141,839,233105,211,595171,728,90986,943,19474,647,103110,107,17350,333,654-140,248,068
CFO
-149m
L
054,138,642125,954,626331,975,678220,700,152077,177,84081,878,424108,020,36495,158,31400167,074,831178,828,210231,438,796144,200,478119,381,52575,907,30345,079,614-148,963,590
Dividend
May 27, 20220.06 CNY/sh

Profile

Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, medicinal feed additives, fine chemicals, and preparations in China. The company also exports its products to approximately 30 countries and regions worldwide. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.
IPO date
Nov 12, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
737,819
-7.50%
797,643
-4.71%
Cost of revenue
819,463
649,503
Unusual Expense (Income)
NOPBT
(81,644)
148,140
NOPBT Margin
18.57%
Operating Taxes
11,748
12,366
Tax Rate
8.35%
NOPAT
(93,391)
135,774
Net income
(140,248)
-378.64%
50,334
-54.29%
Dividends
(31,562)
(21,159)
Dividend yield
1.11%
0.78%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
291,063
357,243
Long-term debt
421,784
251,336
Deferred revenue
15,654
18,121
Other long-term liabilities
335,318
56,950
Net debt
262,403
133,094
Cash flow
Cash from operating activities
(148,964)
45,080
CAPEX
Cash from investing activities
(565,781)
Cash from financing activities
701,086
300,942
FCF
(379,929)
(59,516)
Balance
Cash
415,244
431,353
Long term investments
35,201
44,131
Excess cash
413,553
435,603
Stockholders' equity
885,547
1,157,081
Invested Capital
2,040,469
1,719,017
ROIC
8.33%
ROCE
6.88%
EV
Common stock shares outstanding
355,779
352,705
Price
7.99
4.31%
7.66
-1.35%
Market cap
2,842,674
5.22%
2,701,719
1.16%
EV
3,134,080
2,834,812
EBITDA
38,306
246,451
EV/EBITDA
81.82
11.50
Interest
49,151
21,101
Interest/NOPBT
14.24%